1. Scrip
  2. >>Business
  3. >>Legal & IP

What To Expect As IRA Legal Challenges Mount

US Chamber Of Commerce Suit Raises New Arguments

 
• By Jessica Merrill

A second lawsuit was filed against the IRA and a new US Medicare drug price negotiation program, and this time, the lawsuit was not filed by an industry insider. 

judge gavel
A second lawsuit was filed against the IRA • Source: Shutterstock

Just days after Merck & Co., Inc. filed the first lawsuit against the US government over the implementation of a new Medicare drug price negotiation program ordered under the Inflation Reduction Act (IRA), a second lawsuit was filed by the US Chamber of Commerce.

Key Takeaways
  • The US Chamber of Commerce filed a second lawsuit against the IRA.

“I think we expected a lawsuit from the pharmaceutical industry, which is the most directly impacted by the law, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

AstraZeneca Plans To ‘Harmonize’ New York and London Listings

 
• By Andrew McConaghie

The company is looking to boost US investor exposure while retaining UK headquarters and tax residence.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.